Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Diversity, Equity, & Inclusion (DEI)
    • Neurology: Clinical Practice Accelerator
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Neurology: Neuroimmunology & Neuroinflammation COVID-19 Article Hub
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
    • UDDA Revision Series
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit New Manuscript
    • Submit Revised Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Diversity, Equity, & Inclusion (DEI)
    • Neurology: Clinical Practice Accelerator
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Neurology: Neuroimmunology & Neuroinflammation COVID-19 Article Hub
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
    • UDDA Revision Series
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit New Manuscript
    • Submit Revised Manuscript
    • Author Center
  • Home
  • Articles
  • Issues
  • COVID-19 Article Hub
  • Infographics & Video Summaries

User menu

  • My Alerts
  • Log in

Search

  • Advanced search
Neurology Neuroimmunology & Neuroinflammation
Home
A peer-reviewed clinical and translational neurology open access journal
  • My Alerts
  • Log in
Site Logo
  • Home
  • Articles
  • Issues
  • COVID-19 Article Hub
  • Infographics & Video Summaries

Share

December 2014; 1 (4) ArticleOpen Access

Occurrence of hemolytic anemia in patients with GBS treated with high-dose IVIg

Thy P. Nguyen, Suur Biliciler, Amer Wahed, Kazim Sheikh
First published December 11, 2014, DOI: https://doi.org/10.1212/NXI.0000000000000050
Thy P. Nguyen
From the Departments of Neurology (T.P.N., S.B., K.S.) and Pathology (A.W.), University of Texas Health Science Center at Houston, TX.
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Suur Biliciler
From the Departments of Neurology (T.P.N., S.B., K.S.) and Pathology (A.W.), University of Texas Health Science Center at Houston, TX.
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Amer Wahed
From the Departments of Neurology (T.P.N., S.B., K.S.) and Pathology (A.W.), University of Texas Health Science Center at Houston, TX.
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kazim Sheikh
From the Departments of Neurology (T.P.N., S.B., K.S.) and Pathology (A.W.), University of Texas Health Science Center at Houston, TX.
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Full PDF
Citation
Occurrence of hemolytic anemia in patients with GBS treated with high-dose IVIg
Thy P. Nguyen, Suur Biliciler, Amer Wahed, Kazim Sheikh
Neurol Neuroimmunol Neuroinflamm Dec 2014, 1 (4) e50; DOI: 10.1212/NXI.0000000000000050

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
1466

Share

  • Article
  • Figures & Data
  • Info & Disclosures
Loading

Abstract

Objective: We describe an underrecognized side effect of high-dose IV immunoglobulin (IVIg), hemolytic anemia.

Background: There are no established guidelines on treating patients with Guillain-Barré syndrome (GBS) who relapse or do not improve after a standard course of treatment (IVIg or plasma exchange). Some centers will opt for a second course of the initial treatment. There is an ongoing trial of a second course of IVIg in patients with severe GBS.

Methods: We retrospectively reviewed 4 patients with severe GBS who received high-dose IVIg. One patient inadvertently received a high dose of IVIg for Miller Fisher syndrome. All patients received a total of at least 2 courses of the standard dose of IVIg (total >4 g/kg). We review their clinical course and side effects.

Results: All patients with non-O blood types developed clinically significant hemolytic anemia requiring blood transfusion.

Conclusion: Hemolytic anemia may limit doses of IVIg for treatment of severe GBS in patients with non-O blood types.

GLOSSARY

GBS=
Guillain-Barré syndrome;
HA=
hemolytic anemia;
IVIg=
IV immunoglobulin;
MFS=
Miller Fisher syndrome

Guillain-Barré syndrome (GBS) is the most common cause of acute flaccid neuromuscular paralysis, resulting in significant morbidity and cost.1 There is a proposed model to identify patients with poor prognosis.1 However, treatment options beyond IV immunoglobulin (IVIg) and plasma exchange are limited.2 An ongoing trial is evaluating a second course of IVIg for severe GBS.1 This trial has prompted treating neurologists to consider an additional course of IVIg if patients do not respond initially. We alert neurologists to significant hemolytic anemia (HA) in patients with non-O blood types treated with high-dose IVIg within a short time interval.

METHODS

This is a retrospective case series. We review 4 patients with severe GBS and one patient with Miller Fisher syndrome (MFS) admitted to our institution from 2012 to 2013. All patients received very high-dose IVIg (total dose of at least 4 g/kg, equivalent to 2 standard treatment courses [2 g/kg]) administered over fewer than 14 days. All patients with GBS did not respond initially, prompting a second course of treatment (table). The patient with MFS received a high dose inadvertently. We gathered data regarding the incidence of HA in these patients. As this was a retrospective review of a small case series, institutional review board approval was not required.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table

Patient characteristics and treatment

RESULTS

All of the patients with non-O blood types (3/5) treated with very high-dose IVIg developed clinically significant anemia requiring blood transfusion. When tested (2/3 cases), there was clear evidence of hemolysis (positive direct antiglobulin test, low haptoglobin, high lactate dehydrogenase/bilirubin). In addition, there were no other medical comorbidities or medications commonly implicated in causing autoimmune hemolytic anemia (table). Patient 4 developed hematuria prior to discharge with normal hemoglobin and returned with massive hemolysis leading to pigmentary nephropathy and requiring hemodialysis. Full neurologic recovery occurred in 2 of the 3 patients who developed HA. Patients with O blood type did develop anemia, but it was mild and clinically asymptomatic. In addition, the patients with O blood type did not have evidence of hemolysis.

Mechanism.

Antibodies to blood group antigens (A and B) found in IVIg due to pooling from donors with O type blood are proposed as the hemolytic mechanism in many prior observations.3,–,7 The current industry standard antibody titers are <1:64 for anti-A and <1:32 for anti-B. Privigen, a commonly used liquid IVIg formulation, currently has anti-A <1:32 and anti-B <1:16. However, the titers of anti-A and anti-B may vary within lots. Therefore, patients who are given higher doses of IVIg will be exposed to higher levels of anti-A and anti-B antibodies. Although our patients received Privigen, HA has been reported with use of many liquid IVIg formulations.3,–,7

DISCUSSION

We propose that risk of IVIg-related HA is increased with high doses, significant in non-O blood types, and more likely to occur when administered over a short interval (i.e., <2 weeks). HA has not been frequently observed in patients receiving maintenance IVIg, likely due to the lower dose, longer time intervals between infusions (typically 3–4 weeks), and 2–3 week half-life of anti-A/B IgG. Although all of our patients had GBS/MFS, HA has been reported in many other conditions treated with high-dose IVIg such as postpolio syndrome, chronic inflammatory demyelinating polyneuropathy, myasthenia gravis, renal transplantation, and Kawasaki disease.3,–,7

The applicability of our findings is limited by a small number of cases, retrospective analysis, and hemolysis testing in only 2 of the 3 patients. However, our findings raise relevant, novel considerations such as a possible maximum tolerated dose of IVIg in a short time frame. In addition, practitioners should exercise caution if considering escalating IVIg dosages to >2 g/kg in <14 days. Hemoglobin and creatinine levels should be monitored closely during and after treatment with high-dose IVIg (up to 1–2 weeks) to detect this untoward complication. In the literature, nadir hemoglobin level seemed to occur within 2 weeks of treatment, commonly within 4–5 days.5,–,7 If anemia occurs, testing should include direct antiglobulin test, peripheral blood smear, bilirubin, haptoglobin, lactate dehydrogenase, and reticulocyte count. IVIg lots can be tested for anti-A and anti-B titers. In addition, a crossmatch could be performed with serum and IVIg. Manufacturers should label anti-A and anti-B titers on their product and consider more stringent industry standards. We propose that there is a maximal tolerated dose of IVIg over a 2-week period, which is dependent on patient ABO blood group and IVIg's anti-A/anti-B titers.

AUTHOR CONTRIBUTIONS

Dr. Nguyen: study concept, design, acquisition of data, analysis, interpretation. Dr. Biliciler: critical revision of the manuscript for important intellectual content. Dr. Wahed: critical revision of the manuscript for important intellectual content. Dr. Sheikh: critical revision of the manuscript for important intellectual content, study supervision.

STUDY FUNDING

No targeted funding reported.

DISCLOSURE

The authors report no disclosures. Go to Neurology.org/nn for full disclosures.

Footnotes

  • Go to Neurology.org/nn for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article. The Article Processing Charge was paid by the authors.

  • Received June 27, 2014.
  • Accepted in final form October 24, 2014.
  • © 2014 American Academy of Neurology

This is an open access article distributed under the terms of the Creative Commons Attribution-Noncommercial No Derivative 3.0 License, which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially.

REFERENCES

  1. 1.↵
    1. Walgaard C,
    2. Lingsma HF,
    3. Ruts L,
    4. van Doorn PA,
    5. Steyerberg EW,
    6. Jacobs BC
    . Early recognition of poor prognosis in Guillain-Barre syndrome. Neurology 2011;76:968–975.
    OpenUrl
  2. 2.↵
    1. Hughes RA,
    2. Swan AV,
    3. van Doorn PA
    . Intravenous immunoglobulin for Guillain-Barre syndrome. Cochrane Database Syst Rev 2012;7:CD002063.
    OpenUrlPubMed
  3. 3.↵
    1. Markvardsen LH,
    2. Christiansen I,
    3. Harbo T,
    4. Jakobsen J
    . Hemolytic anemia following high dose intravenous immunoglobulin in patients with chronic neurological disorders. Eur J Neurol 2014;21:147–152.
    OpenUrlPubMed
  4. 4.↵
    1. Wilson JR,
    2. Bhoopalam H,
    3. Fisher M
    . Hemolytic anemia associated with intravenous immunoglobulin. Muscle Nerve 1997;20:1142–1145.
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. Kahwaji J,
    2. Barker E,
    3. Pepkowitz S,
    4. et al
    . Acute hemolysis after high-dose intravenous immunoglobulin therapy in highly HLA sensitized patients. Clin J Am Soc Nephrol 2009;4:1993–1997.
    OpenUrlAbstract/FREE Full Text
  6. 6.↵
    1. Berard R,
    2. Whittemore B,
    3. Scuccimarri R
    . Hemolytic anemia following intravenous immunoglobulin therapy in patients treated for Kawasaki disease: a report of 4 cases. Pediatr Rheumatol Online J 2012;10:10.
    OpenUrlPubMed
  7. 7.↵
    1. Daw Z,
    2. Padmore R,
    3. Neurath D,
    4. et al
    . Hemolytic transfusion reactions after administration of intravenous immune (gamma) globulin: a case series analysis. Transfusion 2008;48:1598–1601.
    OpenUrl

Letters: Rapid online correspondence

  • Hemolysis after repeated courses of IVIg?
    • Christa Walgaard, Erasmus University Medical Centerp.a.vandoorn@erasmusmc.nl
    • Christine Verboon, Bianca van den Berg, Bart C. Jacobs, Pieter A. van Doorn; Rotterdam, the Netherlands
    Submitted March 31, 2015
  • High dose IVIG and hemolytic anemia
    • Thy P Nguyen, Assistant Professor of Neurology, University of Texas Health Science Center at Houstonthy.p.nguyen@uth.tmc.edu
    • Suur Biliciler, Houston, TX; Amer Wahed, Houston, TX; Kazim Sheikh, Houston, TX.
    Submitted February 26, 2015
Comment

REQUIREMENTS

You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
    • Abstract
    • GLOSSARY
    • METHODS
    • RESULTS
    • DISCUSSION
    • AUTHOR CONTRIBUTIONS
    • STUDY FUNDING
    • DISCLOSURE
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Info & Disclosures
Advertisement

Association of Mediterranean-DASH Intervention for Neurodegenerative Delay and Mediterranean Diets With Alzheimer Disease Pathology

Dr. Babak Hooshmand and Dr. David Smith

► Watch

Related Articles

  • No related articles found.

Topics Discussed

  • Decision analysis
  • All Clinical Neurology
  • Hematologic
  • Peripheral neuropathy
  • Guillain-Barre syndrome

Alert Me

  • Alert me when eletters are published

Recommended articles

  • Article
    Current treatment practice of Guillain-Barré syndrome
    Christine Verboon, Alex Y. Doets, Giuliana Galassi et al.
    Neurology, June 07, 2019
  • Articles
    Treatment of Guillain-Barré Syndrome with Intravenous Immunoglobulin
    Richard A. Sater, Abdolmohamad Rostami et al.
    Neurology, December 01, 1998
  • Article
    Chronic inflammatory demyelinating polyneuropathy
    Clinical features and response to treatment in 67 consecutive patients with and without a monoclonal gammopathy
    Kenneth C. Gorson, Gregory Allam, Allan H. Ropper et al.
    Neurology, February 01, 1997
  • Articles
    Distinguishing acute-onset CIDP from fluctuating Guillain-Barré syndrome
    A prospective study
    L. Ruts, J. Drenthen, B.C. Jacobs et al.
    Neurology, April 28, 2010
Neurology - Neuroimmunology Neuroinflammation: 10 (6)

Articles

  • Articles
  • Issues
  • Popular Articles

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Education
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology: Neuroimmunology & Neuroinflammation
Online ISSN: 2332-7812

© 2023 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise